Commonwealth ENT, Louisville, KY Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2003
NCT00230191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Alternative names

Commonwealth Ear, Nose & Throat

Active Ingredients

Drugs in Phase 2 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Other Trials (1)

lansoprazole (prevacid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Head and Neck Neoplasms (Phase 2)

Mouth Diseases (Phase 2)

Mucositis (Phase 2)

Oral Ulcer (Phase 2)

Stomatitis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2